Zecotek Photonics Inc. has received an order for its patented lutetium fine silicate (LFS) scintillation crystals from a commercial medical imaging device manufacturer based in the U.S. The company has also secured two patents for technology related to its front- and rear-projection autostereoscopic 3D display systems, respectively. The crystal customer is a company that has developed a state-of-the-art molecular brain imaging device for diagnosis of Alzheimer's disease, frontotemporal dementia, Lewy body dementia, Parkinson's disease and other neurological and psychiatric disorders. The initial LFS crystal order will meet the need for a single, specialized positron emission tomography (PET) medical imaging scanner, which is being constructed to showcase the device's capabilities. Financial terms of the order were not disclosed. The crystals will be supplied by the Beijing Opto-Electronics Technology Company Co., a subsidiary of North-China Research Institute of Electronics-Optics, an industry leader in growing, cutting, polishing and large-scale production of scintillation crystals grown by the Czochralski method. Meanwhile, Zecotek has expanded its patent holdings in the U.S. relating to large-format 3D displays (No. 9,182,605 and No. 9,182,606). The two recently approved patents relate to projection 3D autostereoscopic displays using a time-sequencing approach and at least two lens arrays to provide multiple perspective views to form 3D images in the field of view. "As we are now in the final process of commercialization of our 3D display technologies, receiving two new U.S. patents covering large-format displays is an important milestone to secure this unique intellectual property and cover all aspects of realistic, glasses free, natural 3D viewing," said A.F. Zerrouk, chairman, president and CEO of Zecotek. "The patents cover both front and rear projection technology, which can be used for large-format displays. This will be of particular value for movie theatres, simulations, advertising and teaching purposes."